{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:35:04Z","timestamp":1785497704168,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus (TelomeScan) expressing GFP (Lipo-pTS) as an oncolytic adenoviral agent suitable for systemic delivery was investigated. Lipo-pTS, which has a diameter of 40\u201350 nm, showed potent antitumor effects on HCT116 colon carcinoma cells <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Tumor selectivity of Lipo-pTS was independent of coxsackie and adenovirus receptor (CAR). Importantly, Lipo-pTS reduced production of adenovirus-neutralizing antibodies (AdNAbs) after intravenous administration into immune-competent mice compared to TelomeScan, and even in the presence of AdNAbs, Lipo-pTS maintained strong cytotoxicity. In conclusion, Lipo-pTS has the potential to become an oncolytic adenoviral agent suitable for systemic delivery with the characteristics of CAR-independent antitumor activity and a stealth effect on the immune system.<\/jats:p>","DOI":"10.1038\/s41598-017-14717-x","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T15:42:56Z","timestamp":1508514176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system"],"prefix":"10.1038","volume":"7","author":[{"given":"Katsuyuki","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Morihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1050","authenticated-orcid":false,"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"14717_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1517\/14712598.1.3.525","volume":"1","author":"D Kirn","year":"2001","unstructured":"Kirn, D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther \n                           1, 525\u2013538 (2001).","journal-title":"Expert Opin Biol Ther"},{"key":"14717_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrc2545","volume":"9","author":"DH Kirn","year":"2009","unstructured":"Kirn, D. H. & Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer \n                           9, 64\u201371 (2009).","journal-title":"Nat Rev Cancer"},{"key":"14717_CR3","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","volume":"20","author":"DW Sborov","year":"2014","unstructured":"Sborov, D. W. et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res \n                           20, 5946\u20135955 (2014).","journal-title":"Clin Cancer Res"},{"key":"14717_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima, T. et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res \n                           10, 285\u2013292 (2004).","journal-title":"Clin Cancer Res"},{"key":"14717_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/mt.2009.262","volume":"18","author":"J Nemunaitis","year":"2010","unstructured":"Nemunaitis, J. et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther \n                           18, 429\u2013434 (2010).","journal-title":"Mol Ther"},{"key":"14717_CR6","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-10-2333","volume":"70","author":"S Kuroda","year":"2010","unstructured":"Kuroda, S. et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res \n                           70, 9339\u20139348 (2010).","journal-title":"Cancer Res"},{"key":"14717_CR7","doi-asserted-by":"publisher","first-page":"805629","DOI":"10.1155\/2012\/805629","volume":"2012","author":"MS Ferguson","year":"2012","unstructured":"Ferguson, M. S., Lemoine, N. R. & Wang, Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol \n                           2012, 805629 (2012).","journal-title":"Adv Virol"},{"key":"14717_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-59745-210-6_1","volume":"437","author":"KK Jain","year":"2008","unstructured":"Jain, K. K. Drug delivery systems - an overview. Methods Mol Biol \n                           437, 1\u201350 (2008).","journal-title":"Methods Mol Biol"},{"key":"14717_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","volume":"69","author":"M Gaumet","year":"2008","unstructured":"Gaumet, M., Vargas, A., Gurny, R. & Delie, F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm \n                           69, 1\u20139 (2008).","journal-title":"Eur J Pharm Biopharm"},{"key":"14717_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nnano.2008.30","volume":"3","author":"W Jiang","year":"2008","unstructured":"Jiang, W., Kim, B. Y., Rutka, J. T. & Chan, W. C. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol \n                           3, 145\u2013150 (2008).","journal-title":"Nat Nanotechnol"},{"key":"14717_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrd2591","volume":"9","author":"RA Petros","year":"2010","unstructured":"Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov \n                           9, 615\u2013627 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"14717_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/17435889.1.3.297","volume":"1","author":"ML Immordino","year":"2006","unstructured":"Immordino, M. L., Dosio, F. & Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine \n                           1, 297\u2013315 (2006).","journal-title":"Int J Nanomedicine"},{"key":"14717_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz, Y. Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned. J Control Release \n                           160, 117\u2013134 (2012).","journal-title":"J Control Release"},{"key":"14717_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang, J., Nakamura, H. & Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev \n                           63, 136\u2013151 (2011).","journal-title":"Adv Drug Deliv Rev"},{"key":"14717_CR15","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/sj.onc.1208460","volume":"24","author":"M Taki","year":"2005","unstructured":"Taki, M. et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (\u2018Telomelysin-RGD\u2019). Oncogene \n                           24, 3130\u20133140 (2005).","journal-title":"Oncogene"},{"key":"14717_CR16","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka, R. H. et al. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol \n                           23, 4169\u20134177 (2016).","journal-title":"Ann Surg Oncol"},{"key":"14717_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki, A., Witzigmann, D., Balasubramanian, V. & Huwyler, J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release \n                           200, 138\u2013157 (2015).","journal-title":"J Control Release"},{"key":"14717_CR18","first-page":"3825","volume":"9","author":"S Kuroda","year":"2014","unstructured":"Kuroda, S., Tam, J., Roth, J. A., Sokolov, K. & Ramesh, R. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2\/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine \n                           9, 3825\u20133839 (2014).","journal-title":"Int J Nanomedicine"},{"key":"14717_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2014.03.013","volume":"190","author":"F Kratz","year":"2014","unstructured":"Kratz, F. A clinical update of using albumin as a drug vehicle - a commentary. J Control Release \n                           190, 331\u2013336 (2014).","journal-title":"J Control Release"},{"key":"14717_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/cas.12419","volume":"105","author":"Y Sasaki","year":"2014","unstructured":"Sasaki, Y. et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci \n                           105, 812\u2013817 (2014).","journal-title":"Cancer Sci"},{"key":"14717_CR21","doi-asserted-by":"publisher","first-page":"16023","DOI":"10.1038\/mtm.2016.23","volume":"3","author":"J Chen","year":"2016","unstructured":"Chen, J., Guo, Z., Tian, H. & Chen, X. Production and clinical development of nanoparticles for gene delivery. Mol Ther Methods Clin Dev \n                           3, 16023 (2016).","journal-title":"Mol Ther Methods Clin Dev"},{"key":"14717_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","volume":"194","author":"NS Gandhi","year":"2014","unstructured":"Gandhi, N. S., Tekade, R. K. & Chougule, M. B. Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release \n                           194, 238\u2013256 (2014).","journal-title":"J Control Release"},{"key":"14717_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2012.06.002","volume":"163","author":"SB Lim","year":"2012","unstructured":"Lim, S. B., Banerjee, A. & Onyuksel, H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release \n                           163, 34\u201345 (2012).","journal-title":"J Control Release"},{"key":"14717_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/156800911793743673","volume":"11","author":"T Shikano","year":"2011","unstructured":"Shikano, T. et al. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus. Curr Cancer Drug Targets \n                           11, 111\u2013122 (2011).","journal-title":"Curr Cancer Drug Targets"},{"key":"14717_CR25","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.1016\/j.biomaterials.2014.08.010","volume":"35","author":"N Mendez","year":"2014","unstructured":"Mendez, N. et al. Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency. Biomaterials \n                           35, 9554\u20139561 (2014).","journal-title":"Biomaterials"},{"key":"14717_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jconrel.2011.06.014","volume":"155","author":"OJ Kwon","year":"2011","unstructured":"Kwon, O. J., Kang, E., Kim, S. & Yun, C. O. Viral genome DNA\/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. J Control Release \n                           155, 317\u2013325 (2011).","journal-title":"J Control Release"},{"key":"14717_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ijc.21846","volume":"119","author":"T Fujiwara","year":"2006","unstructured":"Fujiwara, T. et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer \n                           119, 432\u2013440 (2006).","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"14717_CR28","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1002\/jgm.553","volume":"6","author":"O Meier","year":"2004","unstructured":"Meier, O. & Greber, U. F. Adenovirus endocytosis. J Gene Med \n                           6(Suppl 1), S152\u2013163 (2004).","journal-title":"J Gene Med"},{"key":"14717_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2011.12.008","volume":"158","author":"J Kim","year":"2012","unstructured":"Kim, J. et al. Linearized oncolytic adenoviral plasmid DNA delivered by bioreducible polymers. J Control Release \n                           158, 451\u2013460 (2012).","journal-title":"J Control Release"},{"key":"14717_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","volume":"40","author":"JM Harris","year":"2001","unstructured":"Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet \n                           40, 539\u2013551 (2001).","journal-title":"Clin Pharmacokinet"},{"key":"14717_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijpharm.2011.04.008","volume":"412","author":"Y Yoshizawa","year":"2011","unstructured":"Yoshizawa, Y., Kono, Y., Ogawara, K., Kimura, T. & Higaki, K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm \n                           412, 132\u2013141 (2011).","journal-title":"Int J Pharm"},{"key":"14717_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2015.05.271","volume":"210","author":"S Zalba","year":"2015","unstructured":"Zalba, S. et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release \n                           210, 26\u201338 (2015).","journal-title":"J Control Release"},{"key":"14717_CR33","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1158\/1535-7163.MCT-15-0314","volume":"14","author":"E Geretti","year":"2015","unstructured":"Geretti, E. et al. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). Mol Cancer Ther \n                           14, 2060\u20132071 (2015).","journal-title":"Mol Cancer Ther"},{"key":"14717_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.4155\/tde.14.72","volume":"5","author":"J Pae","year":"2014","unstructured":"Pae, J. & Pooga, M. Peptide-mediated delivery: an overview of pathways for efficient internalization. Ther Deliv \n                           5, 1203\u20131222 (2014).","journal-title":"Ther Deliv"},{"key":"14717_CR35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2741\/2807","volume":"13","author":"T Fujiwara","year":"2008","unstructured":"Fujiwara, T., Urata, Y. & Tanaka, N. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. Front Biosci \n                           13, 1881\u20131886 (2008).","journal-title":"Front Biosci"},{"key":"14717_CR36","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nm1404","volume":"12","author":"H Kishimoto","year":"2006","unstructured":"Kishimoto, H. et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med \n                           12, 1213\u20131219 (2006).","journal-title":"Nat Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:47:16Z","timestamp":1671799636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14717-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"9 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14177"}}